Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 16/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2065632 | 0.79 | NAPRT (0.41) | PDE2AGRM5 | |
| SCHEMBL6425764 | 0.76 | AR (0.42) | PDE2A | |
| SCHEMBL21405105 | 0.71 | TRPA1 (0.42) | — | |
| SCHEMBL21405109 | 0.71 | TRPA1 (0.42) | — | |
| SCHEMBL2293408 | 0.71 | KCNJ1 (0.33) | — | |
| SCHEMBL2384740 | 0.70 | CNR2 (0.41) | PDE2A | |
| SCHEMBL29956330 | 0.69 | HSD17B10 (0.42) | — | |
| SCHEMBL29957588 | 0.69 | HSD17B10 (0.42) | — | |
| SCHEMBL934018 | 0.69 | TYR (0.48) | — | |
| SCHEMBL1749308 | 0.69 | CTSL (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029538-B1 | BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| US-20110275815-A1 | BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS | SEAL JONATHAN THOMAS | 2011-11-10 | — | — | US | disclosed |
| US-8012981-B2 | Benzylpiperazine derivatives as motilin receptor agonists | GLAXO GROUP LIMITED (GB) | 2011-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275815-A1 | BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS | GPR68, GPR52, GPR88 | PDE2A 1251/4885HDAC3 1713/4885HDAC1 1724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.